FeesSafety
Pluang+

NeOnc plans a 500-patient brain cancer trial across 30 hospitals in 3 countries using novel intranasal therapy.

Market News
26 Oct 2026, 16:19 WIB
GlobeNewsWire
View Source
Bullish
NeOnc plans a 500-patient brain cancer trial across 30 hospitals in 3 countries using novel intranasal therapy.

NeOnc Technologies is launching an ambitious international clinical trial involving about 500 brain cancer patients across 30 hospitals in three countries. The trial tests NEO100, an investigational therapy delivered intranasally to bypass the blood-brain barrier, a major obstacle in brain cancer treatment. Early results showed promising remission rates, and the company is using a precision medicine approach to target patients with specific tumor mutations. This large-scale study aims to build on preliminary findings and improve treatment options, potentially extending patients' lives and quality of time with family.

NeOnc's brain cancer trial expansion is the focus here, with Pluang providing a snapshot of the Health sector's market activity. As of Oct 26, 2026 19:02 WIB, among 150 priced Health-sector US stocks on Pluang, 78 rose and 48 fell. Notable movers include MMED at USD 18.02 with a 1-day change of -1.74% and a typical hold time of 17 days, ABCL at USD 12.00 up 1.52% with a 41-day hold, and XRAY at USD 9.57 up 1.48% with a 73-day hold.

More News

Smithfield Foods launches $250K scholarship for business students at Christopher Newport University

Smithfield Foods launches $250K scholarship for business students at Christopher Newport University

Smithfield Foods has created a $250,000 Future Leaders Scholarship program at Christopher Newport University to support eight incoming business students with $7,500 annual scholarships renewable for up to four years. The program aims to help local st...

Others
Bullish
1 hour ago
E-Power's Guizhou JV secures RMB 110M of RMB 200M capital raise, valuing it at RMB 2B post-money.

E-Power's Guizhou JV secures RMB 110M of RMB 200M capital raise, valuing it at RMB 2B post-money.

E-Power Inc.'s joint venture, Sunrise Guizhou, received RMB 110 million of a planned RMB 200 million capital increase, raising its registered capital and valuing the company at RMB 2 billion post-money. The funds will support business expansion, R&D,...

Company Fundamentals
Bullish
1 hour ago
Tallinna Sadam secures €50M loan to refinance bonds maturing in 2026, extending debt to 2031.

Tallinna Sadam secures €50M loan to refinance bonds maturing in 2026, extending debt to 2031.

AS Tallinna Sadam has signed a €50 million unsecured loan agreement with Swedbank, with a 5-year term and interest based on 3-month Euribor plus a margin. The loan will be fully drawn on October 26, 2026, and matures on October 26, 2031. This financi...

Company Fundamentals
Neutral
2 hours ago
AS Tallinna Sadam secures €50M loan to redeem bonds, supporting port operations and growth.

AS Tallinna Sadam secures €50M loan to redeem bonds, supporting port operations and growth.

AS Tallinna Sadam signed a €50 million unsecured loan agreement with AS Swedbank, maturing in five years with an interest rate based on 3-month Euribor plus margin. The loan, drawn on October 26, 2026, will be used to redeem bonds worth €50.4 million...

Company Fundamentals
Neutral
2 hours ago
Vita Coco and Homesick launch limited-edition candles inspired by Vita Coco Treats flavors

Vita Coco and Homesick launch limited-edition candles inspired by Vita Coco Treats flavors

Vita Coco, a leading coconut water brand, has partnered with Homesick to create a limited-edition candle collection inspired by Vita Coco Treats flavors: Strawberries & Creme and Frosted Lemonade. The candles capture the essence of these flavors thro...

Others
Bullish
3 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App